Alzheimer disease and associated disorders · 2025
Inflammatory Alterations and Multidomain Cognition in Alzheimer Disease and Related Dementias.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smith Anna, Guzman Diana, Lee Seonjoo, Talmasov Daniel, Dass Dina, Chikwem Ndubisi, Johnson Aubrey, Houlihan Hannah, Sanchez Thairi, Kreisl William C, Cosentino Stephanie, Noble James M, Lao Patrick
Аннотация
OBJECTIVE: To determine how 18kDa Translocator (TSPO) PET, which measures inflammatory alterations, is associated with domain-specific cognition in the presence and absence of elevated amyloid.
METHODS: This cross-sectional study uses data collected on 46 adults aged 50 and over who underwent TSPO PET (11C-ER176 SUVR) and amyloid PET (18F-Florbetaben SUVR) as well as medical, neurological, and neuropsychological assessments. Controls (n=21) were amyloid-negative and cognitively unimpaired while individuals with Alzheimer disease or related dementias (ADRD; n=25) were cognitively impaired, regardless of amyloid positivity. Cognition was assessed using the Mini-Mental State Examination (MMSE) and domain-specific tests included in the NACC UDSv3.
RESULTS: Greater TSPO is associated with lower performance in episodic memory, attention/processing speed, executive function, language, and visuospatial ability in amyloid-positive individuals, but restricted to episodic memory in amyloid-negative individuals.
CONCLUSION: Targeting microglia as an additional or alternative strategy for cognitive impairment in Alzheimer disease and related dementias may provide further benefits, even in amyloid-negative individuals.
METHODS: This cross-sectional study uses data collected on 46 adults aged 50 and over who underwent TSPO PET (11C-ER176 SUVR) and amyloid PET (18F-Florbetaben SUVR) as well as medical, neurological, and neuropsychological assessments. Controls (n=21) were amyloid-negative and cognitively unimpaired while individuals with Alzheimer disease or related dementias (ADRD; n=25) were cognitively impaired, regardless of amyloid positivity. Cognition was assessed using the Mini-Mental State Examination (MMSE) and domain-specific tests included in the NACC UDSv3.
RESULTS: Greater TSPO is associated with lower performance in episodic memory, attention/processing speed, executive function, language, and visuospatial ability in amyloid-positive individuals, but restricted to episodic memory in amyloid-negative individuals.
CONCLUSION: Targeting microglia as an additional or alternative strategy for cognitive impairment in Alzheimer disease and related dementias may provide further benefits, even in amyloid-negative individuals.